Age, Biography and Wiki
Gregory Hannon (Gregory James Hannon) was born on 1964 in United Kingdom, is a British professor of molecular cancer biology (born 1964). Discover Gregory Hannon's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 60 years old?
We recommend you to check the complete list of Famous People born on .
He is a member of famous Professor with the age 60 years old group.
Gregory Hannon Height, Weight & Measurements
At 60 years old, Gregory Hannon height not available right now. We will update Gregory Hannon's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status |
| Height |
Not Available |
| Weight |
Not Available |
| Body Measurements |
Not Available |
| Eye Color |
Not Available |
| Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
| Family |
| Parents |
Not Available |
| Wife |
Not Available |
| Sibling |
Not Available |
| Children |
Not Available |
Gregory Hannon Net Worth
His net worth has been growing significantly in 2023-2024. So, how much is Gregory Hannon worth at the age of 60 years old? Gregory Hannon’s income source is mostly from being a successful Professor. He is from United Kingdom. We have estimated Gregory Hannon's net worth, money, salary, income, and assets.
| Net Worth in 2024 |
$1 Million - $5 Million |
| Salary in 2024 |
Under Review |
| Net Worth in 2023 |
Pending |
| Salary in 2023 |
Under Review |
| House |
Not Available |
| Cars |
Not Available |
| Source of Income |
Professor |
Gregory Hannon Social Network
Timeline
Gregory James Hannon (born 1964) is a professor of molecular cancer biology and director of the Cancer Research UK Cambridge Institute at the University of Cambridge.
He is a Fellow of Trinity College, Cambridge while also serving as a director of cancer genomics at the New York Genome Center and an adjunct professor at Cold Spring Harbor Laboratory.
Hannon is known for his contributions to small RNA biology, cancer biology, and mammalian genomics.
He has a history in discovery of oncogenes, beginning with work that led to the identification of CDK inhibitors and their links to cancer.
More recently, his work has focused on small RNA biology, which led to an understanding of the biochemical mechanisms and biological functions of RNA interference (RNAi).
He has developed widely used tools and strategies for manipulation of gene expression in mammalian cells and animals and has generated genome-wide short hairpin RNA (shRNA) libraries that are available to the cancer community and was among the first to demonstrate roles for microRNAs in cancer.
His laboratory also discovered the piwi-interacting RNA (piRNA) pathway and linked this to transposon repression and the protection of germ cell genomes.
His innovations include the development of selective re-sequencing strategies, broadly termed exome capture.
In 2017, Hannon was awarded a £20 million Cancer Grand Challenges award to unite the IMAXT team - a team of researchers from Switzerland, Ireland, Canada, the USA and the UK, with far ranging expertise from cancer biology and pathology to astronomy and even VR video game design.
The team's aim is to create an interactive 3D map of cancer, which could be explored in virtual reality.
The programme could transform the way researchers study cancer by providing unprecedented insight into how individual cells are arranged and how they interact to allow the tumour to grow.
In 2018, it was announced Prof Hannon would guide the Functional Genomics Centre, a collaboration between Cancer Research UK and AstraZeneca.
The centre, housed inside the Milner Therapeutics Institute, aims to act as a hub for genetic screens, cancer models, CRISPR tool design, and computational approaches to big data to understand genetic changes in cancer development and identify potential drug targets.
